Concentrix is trading at $26.57, up 6.48%, with no verified catalyst directly linked to the gain. - Recent coverage discusses the September 29 earnings but does not attribute the move to them. Results were mixed: non-GAAP EPS of $2.92 beat estimates, revenue fell 1.2% year over year, and the company recorded a $1.05 billion goodwill impairment. - FY2026 non-GAAP EPS guidance rose to $10.97–$11.09. Major indices are only modestly higher, offering no clear explanation for the outsized gain.